Overview

Platelet Function Assessment for Atherothrombotic Patients

Status:
Unknown status
Trial end date:
2011-07-01
Target enrollment:
0
Participant gender:
All
Summary
Background-Despite the pivotal pathogenic role of platelets in atherothrombosis has been widely recognized, there is a striking lack of consensus regarding how to measure platelet function and how to monitor the effects of various antiplatelet drugs. In view of the fact that recurrent ischemic events occurred in 8.5% to 8.8% of patients treated with dual antiplatelet drugs and there is significant inter-individual variability in platelet reactivity, we believe that the importance of platelet function assessment and its clinical implication should not be overlooked.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Taiwan University Hospital
Treatments:
Clopidogrel
Ticlopidine
Criteria
Inclusion Criteria:

- Coronary artery disease

Exclusion Criteria:

- History of bleeding diathesis

- History of drug or alcohol abuse or liver disease

- Abnormal prothrombin time

- Abnormal platelet count

- Serum creatinine >1.5 mg/dl.